Sanofi Gains Enoxaparin Approval in Japan
This article was originally published in PharmAsia News
Japan's Ministry of Health, Labor and Welfare has approved for marketing Sanofi-Aventis' low-molecular weight heparin Clexane (enoxaparin), according to Sanofi
You may also be interested in...
Astellas and Daiichi Sankyo both are on track to proceed to Phase III for their respective oral Factor Xa inhibitors, the companies indicated in second quarter earnings presentations on Nov. 7
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.